A Study of miRNA 371 in Patients With Germ Cell Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Germ Cell Tumor
- Metachronous Malignant Neoplasm
- Seminoma
- Stage I Testicular Cancer AJCC v8
- Stage IA Testicular Cancer AJCC v8
- Stage IB Testicular Cancer AJCC v8
- Stage IS Testicular Cancer AJCC v8
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVE: I. To estimate the positive predictive value within each of the early stage testicular seminoma and nonseminoma groups using plasma miRNA 371 expression at relapse to detect germ cell malignancy. SECONDARY OBJECTIVES: I. To bank prospectively obtained serial liquid biospecimens fo...
PRIMARY OBJECTIVE: I. To estimate the positive predictive value within each of the early stage testicular seminoma and nonseminoma groups using plasma miRNA 371 expression at relapse to detect germ cell malignancy. SECONDARY OBJECTIVES: I. To bank prospectively obtained serial liquid biospecimens for low and moderate risk of relapse patients annotated by patient level clinical data. II. To bank prospectively collected, clinically annotated specimens for high risk patients and non-testicular primary patients in collaboration with Children's Oncology Group study AGCT 1531. OUTLINE: Patients undergo collection of blood every 3-6 months for up to 3 years.
Tracking Information
- NCT #
- NCT04435756
- Collaborators
- National Cancer Institute (NCI)
- Investigators
- Principal Investigator: Craig R Nichols Southwest Oncology Group